A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Incorporating an Open Label Pilot Arm
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Elismetrep (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Therapeutic Use
- Acronyms Sensuro
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 23 Aug 2018 Status changed from active, no longer recruiting to completed.
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2017 Status changed from not yet recruiting to recruiting.